BioXcel Therapeutics Profit Margin

The latest profit margin for BTAI is -9549.87% as of June 2026. That compares with -5869.82% in the prior-year period — down 62.7% year over year. That is below the Healthcare sector average of 14.41%. Investors often review this figure alongside BioXcel Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BTAI's profit margin moved from -5869.82% to -9549.87% — a 62.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioXcel Therapeutics's valuation or profitability profile.

Against Healthcare companies, BTAI currently prints -9549.87% for profit margin, while the sector average sits near 14.41%. That is roughly 66350.5% below the sector mean. Large gaps often invite a closer look at BioXcel Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively BioXcel Therapeutics converts resources into returns. At -9549.87%, BTAI may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -5869.82% in the prior-year period — down 62.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BTAI's profit margin (-9549.87%), review year-over-year change from -5869.82%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.